(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 18.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.8%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Vericel's revenue in 2025 is $249,119,000.On average, 3 Wall Street analysts forecast VCEL's revenue for 2025 to be $13,880,239,970, with the lowest VCEL revenue forecast at $13,867,978,140, and the highest VCEL revenue forecast at $13,891,189,834. On average, 3 Wall Street analysts forecast VCEL's revenue for 2026 to be $17,097,431,260, with the lowest VCEL revenue forecast at $16,866,323,521, and the highest VCEL revenue forecast at $17,263,949,937.
In 2027, VCEL is forecast to generate $21,197,474,297 in revenue, with the lowest revenue forecast at $20,149,769,061 and the highest revenue forecast at $22,014,273,635.